Avatrombopag

Phase 3

SOBI (SWTOY)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

0 competitors in Chemotherapy-induced Thrombocytopenia

View Full Landscape

Drug Information

Target Indication

Chemotherapy-induced Thrombocytopenia

Clinical Trial

NCT03471078

Last updated: 12/13/2025

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA6/20/2019

Doptelet

Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure. Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

SWTOY

SOBI

Healthcare•North America•NASDAQ

Related Pipeline

Avatrombopag Oral TabletPhase 3

Immune Thrombocytopenia

EmapalumabPhase 2

Cytopenia